Thermodynamic interrogation of a folding disease. Mutant mapping of position 107 in human carbonic anhydrase II linked to marble brain disease.
Marble brain disease (MBD) also known as Guibaud-Vainsel syndrome is caused by autosomal recessive mutations in the human carbonic anhydrase II (HCA II) gene. HCA II is a 259 amino acid single domain enzyme and is dominated by a 10-stranded beta-sheet. One mutation associated with MBD entails the H107Y substitution where H107 is a highly conserved residue in the carbonic anhydrase protein family. We have previously demonstrated that the H107Y mutation is a remarkably destabilizing folding mutation [Almstedt et al. (2004) J. Mol. Biol. 342, 619-633]. Here, the exceptional destabilization by the H107Y mutation has been further investigated. A mutational survey of position H107 and a neighboring conserved position E117 has been performed entailing the mutants H107A, H107F, H107N, E117A and the double mutants H107A/E117A and H107N/E117A. All mutants were severely destabilized versus GuHCl and heat denaturation. Thermal denaturation and GuHCl phase diagram and ANS analyses showed that the mutants shifted HCA II toward populating ensembles of intermediates of molten globule type under physiological conditions. The native state stability of the mutants was in the following order: wt > H107N > E117A > H107A > H107F > H107Y > H107N/E117A > H107A/E117A.


CONCLUSIONS
(i) H107N is least destabilizing likely due to compensatory H-bonding ability of the introduced Asn residue. (ii) Double mutant cycles surprisingly reveal additive destabilization of H107N and E117A showing that H107 and E117 are independently stabilizing the folded protein. (iii) H107Y and H107F are exceptionally destabilizing due to bulkiness of the side chains whereas H107A is more accommodating, indicating long-range destabilizing effects of the natural pathogenic H107Y mutation.
Almstedt
Karin
K
IFM-Department of Chemistry, Linköping University, 581 83 Linköping, Sweden.
Mårtensson
Lars-Göran
LG
Carlsson
Uno
U
Hammarström
Per
P
D000086:Acetazolamide / Q000494:pharmacology; D019943:Amino Acid Substitution; D020739:Brain Diseases, Metabolic, Inborn / Q000201:enzymology / Q000235:genetics* / Q000378:metabolism; D024402:Carbonic Anhydrase II / Q000037:antagonists & inhibitors / Q000235:genetics*; D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology; D004795:Enzyme Stability; D019791:Guanidine / Q000494:pharmacology; D006358:Hot Temperature; D006801:Humans; D008958:Models, Molecular; D009154:Mutation; D011489:Protein Denaturation; D017510:Protein Folding; D020836:Protein Structure, Quaternary; D013050:Spectrometry, Fluorescence; D013816:Thermodynamics
D002257:Carbonic Anhydrase Inhibitors; D024402:Carbonic Anhydrase II; D019791:Guanidine; D000086:Acetazolamide